Skip to content

An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population

An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02249468
Enrollment
191
Registered
2014-09-25
Start date
2014-10-31
Completion date
2016-11-30
Last updated
2017-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitively Healthy People, Mild and Moderate Alzheimer's Disease

Brief summary

Difference in nutritional status between patients with mild and moderate Alzheimer's Disease (AD) and cognitively intact healthy people in an Asian population

Detailed description

The main objective of the current Asian nutritional status study is to get more insight into the nutritional status of AD patients in an Asian population in Asia. Plasma levels of several micronutrients and the fatty acid profile will be compared between patients with mild and moderate AD and cognitively intact healthy controls in an Asian population

Interventions

None listed

Sponsors

Danone Nutricia Research
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age ≥ 50 years old * Asian ethnicity * Group 1: Cognitively intact healthy volunteers defined by Cumulative Illness Rating Scale for Geriatrics rating of ≤ 2 for all categories except for the category psychiatric illness which should have a rating of 0 and a CDR of 0 within 1 year prior to the visit. OR Group 2a: AD patients clinically diagnosed with mild AD (according to the National Institute of Neurological and Communicative Disorders, and Stroke-Alzheimer's Disease and Related Disorders criteria (McKhann et al., 1984)) with Clinical Dementia Rating-1 OR Group 2b: AD patients clinically diagnosed with moderate AD (according to the National Institute of Neurological and Communicative Disorders, and Stroke-Alzheimer's Disease and Related Disorders criteria (McKhann et al., 1984)) with Clinical Dementia Rating-2 \- Written informed consent provided according to local regulations.

Exclusion criteria

* Group 1 only: Current diagnosis of AD or other dementias according to National Institute of Neurological and Communicative Disorders, and Stroke-Alzheimer's Disease and Related Disorders criteria (McKhann et al.,1984 ) * Group 2 only: Change in dose within 2 months prior to visit of AD medication (e.g. donepezil, rivastigmine, galantamine or memantine) Group 1 and 2: * Diagnosis of significant neurological disease (for Groups 2a and 2b: other than AD), including vascular dementia according to National Institute of Neurological and Communicative Disorders, and Stroke-Alzheimer's Disease and Related Disorders criteria, cerebral tumour, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, seizures, major depression, schizophrenia and other entities * Use of vitamins supplements (only vitamins supplements C and D are allowed) for 3 months prior to the visit * Use of vitamin B injections * Alcohol or drug abuse as per investigator's judgement * Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements * Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study

Design outcomes

Primary

MeasureTime frameDescription
Homocysteine1 dayTo look at nutritional Status in the blood
Uridine1 dayTo look at nutritional Status in the blood
Serum Phospholipids and Fatty Acid Profile1 daySerum Phospholipids, fatty acid profile e.g. docosahexaenoic acid / eicosapentaenoic acid / phosphatidylcholine docosahexaenoic acid To look at nutritional Status in the blood
Red Blood Cell Phospholipids and fatty acid profile1 dayRed Blood Cell Phospholipids, fatty acid profile e.g. docosahexaenoic acid / eicosapentaenoic acid / phosphatidylcholine docosahexaenoic acid To look at nutritional Status in the blood
Plasma polar lipid profile1 dayPlasma polar lipid profile including several types of phospholipids and their specific species; and cholesterol-esters To look at nutritional Status in the blood
Choline1 dayTo look at nutritional Status in the blood
Vitamin B61 dayTo look at nutritional Status in the blood
Folate1 dayTo look at nutritional Status in the blood
Vitamin B121 dayTo look at nutritional Status in the blood
Selenium1 dayTo look at nutritional Status in the blood
Vitamin E1 dayTo look at nutritional Status in the blood
Vitamin D1 dayTo look at nutritional Status in the blood
HbA1C (haemoglobin A1C )1 dayOther blood parameters
Liver Function - Alanine Aminotransferase and Aspartate Aminotransferase1 dayOther blood parameters
Kidney function - Creatinine1 dayOther blood parameters
Inflammatory marker1 dayC-reactive protein analysed using high sensitive C-reactive protein

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026